Autres langues ABIONYX Pharma SA

Actions

ABNX

FR0012616852

Recherche biotechnologique et médicale

PEA

PEA/PME

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 04/12/2025			Varia. 5j.	Varia. 1 janv.
3,890 ^EUR	+3,18 %		-4,77 %	+226,89 %

26/11	Abionyx Pharma : indique une visibilité financière jusqu'au second semestre 2026
25/11	ABIONYX Pharma : Bigben, Eutelsat, Medincell, Sanofi... les valeurs à suivre aujourd'hui à Paris

Autres langues

Abionyx Pharma SA Provides Consolidated Revenue for the Third Quarter Ended September 30, 2025	25/11
ABIONYX Pharma Reports on Its Business and Cash Position for the Third Quarter of 2025	25/11
ABIONYX Pharma : reports on its business and cash position for the third quarter of 2025	25/11
French and Benelux stocks-Factors to watch 21 Nov	21/11
Abionyx Pharma and Sebia announce partnership to transform sepsis diagnosis	20/11
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis	20/11
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis	20/11
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World's First Center Dedicated to Sepsis	12/11
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS	12/11
ABIONYX Pharma Announces Advanced Strategic Discussions with IHU SEPSIS, the World's Leading Center Dedicated to Sepsis	12/11
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis	12/11
ABIONYX Pharma Announces Study Published in Nature Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis	21/10
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis	21/10
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis	21/10
ABIONYX Pharma Announces Landmark Validation: A Study published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis	21/10
ABIONYX Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2025	25/09
ABIONYX Pharma: 2025 Half-Year Financial Results	25/09
ABIONYX Pharma : 2025 Half-Year financial results	25/09
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025	28/08
Abionyx Pharma in Talks Over Sepsis Drug Collaboration	28/08
ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership	27/08
ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA	03/07
ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting	27/06
ABIONYX Pharma : announces approval of all resolutions put to the vote at its Combined General Meeting	27/06
ABIONYX Pharma : Summary (Summary dd1b3)	26/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ABIONYX Pharma SA

Actions

ABNX

FR0012616852

Recherche biotechnologique et médicale

PEA

PEA/PME

Autres langues

Filtres